Healthcare -
Biotechnology - NASDAQ - US
$ 30.33
-11.8 %
$ 199 M
Market Cap
-2.53
P/E
1. INTRINSIC VALUE
Balance Sheet
Instil Bio, Inc.
| Current Assets | 124 M |
| Cash & Short-Term Investments | 113 M |
| Receivables | 0 |
| Other Current Assets | 11.2 M |
| Non-Current Assets | 139 M |
| Long-Term Investments | 0 |
| PP&E | 130 M |
| Other Non-Current Assets | 8.76 M |
| Current Liabilities | 7.9 M |
| Accounts Payable | 659 K |
| Short-Term Debt | 1.68 M |
| Other Current Liabilities | 5.56 M |
| Non-Current Liabilities | 86.2 M |
| Long-Term Debt | 85.2 M |
| Other Non-Current Liabilities | 1.03 M |
EFFICIENCY
Earnings Waterfall
Instil Bio, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 73.5 M |
| Operating Income | -73.5 M |
| Other Expenses | 594 K |
| Net Income | -74.1 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Instil Bio, Inc.
| Net Income | -74.1 M |
| Depreciation & Amortization | 3.61 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 17.3 M |
| Change in Working Capital | -12.6 M |
| Others | -1.87 M |
| Free Cash Flow | -55.7 M |
Wall Street Analysts Price Targets
Instil Bio, Inc.
Wall Street analysts predict an average 1-year price target for TIL of $113 , with forecasts ranging from
a
low of
$40 to a high of $180 .
TIL Lowest Price Target
Wall Street Target
40 USD
31.88%
TIL Average Price Target
Wall Street Target
113 USD
273.67%
TIL Highest Price Target
Wall Street Target
180 USD
493.47%
4. DIVIDEND
ANALYSIS
TIL does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Instil Bio, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice
Does Instil Bio, Inc. (TIL) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com
- 1 week ago
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced the appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer. Dr. Freedman brings deep experience in oncology drug development and other therapeutic areas, and a track record of leading programs through all phases of development, regulatory approval and commercialization.
globenewswire.com
- 2 weeks ago
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil"), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that Bronson Crouch, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference at 4:20PM ET on Thursday, June 5, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/jeff319/til/1708376.
globenewswire.com
- 2 weeks ago
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?
Instil Bio (TIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
- 2 weeks ago
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade
The consensus price target hints at a 343.6% upside potential for Instil Bio (TIL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zacks.com
- 2 weeks ago
Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success
Key catalyst: Phase 2 data from China in first-line NSCLC expected in 2H 2025, with enrollment completion projected for Q3 2025. The global non-small cell lung cancer therapeutics market size is projected to reach $66.20 billion by 2033. The U.S. strategy differs, focusing on dose-optimization as a bridging study for a future global phase 3 registration trial.
seekingalpha.com
- 3 weeks ago
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced that they will jointly host an investor and research analyst breakfast in Chicago, Illinois on Saturday, May 31, 2025 at 8:00 to 9:30 am CT adjacent to the McCormick Convention Center.
globenewswire.com
- 3 weeks ago
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
Phase 3 trial of ‘2510 in combination with chemotherapy in first-line NSCLC anticipated to start in mid-2026 in China, subject to regulatory discussions
globenewswire.com
- 3 weeks ago
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 Initiation of U.S. clinical study of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC anticipated before the end of 2025, assuming receipt of necessary regulatory approvals DALLAS, May 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2025 financial results and provided a corporate update. Recent Highlights: ImmuneOnco's Phase 1b/2 trial of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC in China is ongoing and ImmuneOnco anticipates initial clinical data from first-line NSCLC patients in 2H 2025.
globenewswire.com
- 1 month ago
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025
globenewswire.com
- 3 months ago
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China
globenewswire.com
- 5 months ago
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Jefferies upgraded Instil Bio TIL, noting that 2024 was a banner year for the PD-(L)1xVEGF class.
benzinga.com
- 5 months ago
8. Profile
Summary
Instil Bio, Inc. TIL
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 199 M
Dividend Yield
0.00%
Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Contact
3963 Maple Avenue, Dallas, TX, 75219
https://instilbio.com
IPO
Date
March 19, 2021
Employees
14
Officers
Dr. Sandeep Laumas M.D.
Chief Financial Officer & Chief Business Officer
Mr. Bronson Crouch
Chairman & Chief Executive Officer